The effect of μ-opioid receptor antisense on morphine potency and antagonist-induced supersensitivity and receptor upregulation

Brain Research Bulletin

Volumn 42, Issue 6, 1997, Pages 479-484

  Shah, Sukrut ^a   Duttaroy, Alokesh ^a   Chen, Billy T ^a   Carroll, Joanne ^a   Yoburn, Byron C ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Opioid receptor; Antisense; Mismatch; Morphine; Naltrexone; Oligodeoxynucleotide; Opioid analgesia; Supersensitivity; Tail flick; Upregulation

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DEUTERIUM; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MORPHINE SULFATE; MU OPIATE RECEPTOR; NALTREXONE; TRITIUM;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; GENE EXPRESSION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SPINAL CORD; TAIL FLICK TEST;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MORPHINE; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, OPIOID, MU; SENSITIVITY AND SPECIFICITY; UP-REGULATION;

EID: 0030900049     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(96)00375-9     Document Type: Article

References (35)

1. Adams J. U., Chen X., DeRiel J. K., Adler M. W., Liu-Chen L.-Y. Intracerebroventricular treatment with an antisense oiligodeoxynucleotide to the κ -opioid receptors inhibited κ -agonist-induced analgesia in rats. Brain Res. 667:1994;129-132.
2. 4] deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor. Life Sci. 55:1994;PL37-PL43.
3. Bilsky E. J., Berstein R. N., Hruby V. J., Rothman R. B., Lai J., Porreca F. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide mediated "knock down" of opioid receptors in vivo. J. Pharmacol. Exp. Ther. 260:1996;291-295.
4. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
5. Brodsky M., Elliot K., Hynansky A., Inturrisi C. E. CNS levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone. Brain Res. Bull. 38:1995;135-141.
6. Cha X. Y., Heng X., Ni Q., Partilla J. S., Rice K. C., Matecka D., Calderon S. N., Porecca F., Lai J., Rothman R. B. Opioid peptide receptor studies. 4. Antisense oligodeoxynucleotide to the delta opioid receptor delineates opioid receptor subtypes. Regul. Pept. 59:1995;247-253.
7. Cha X. Y., Heng X., Rice K. C., Porecca F., Lai J., Anathan S., Rothman R. B. Opioid peptide receptor studies. 1. Identification of a novel δ -opioid receptor binding site in rat brain membranes. Peptides. 16:1995;191-198.
8. Chan K., Brodsky M., Davis T., Franklin S., Inturrisi C. E., Yoburn B. C. The effect of the irreversible μ -opioid receptor antagonist clocinamox on morphine potency, receptor binding and receptor mRNA. Eur. J. Pharmacol. 287:1995;135-143.
9. Chen X.-H., Adams J. U., Geller E. B., DeRiel J. K., Adler M., Liu-Chen L.-Y. An antisense oligodeoxynucleotide to μ -opioid receptors inhibits μ -opioid receptor agonist-induced analgesia in rats. Eur. J. Pharmacol. 275:1995;105-108.
10. Chien C.-C., Brown G., Pan Y.-X., Pasternak G. W. Blockade of U5088H analgesia by antisense oligodeoxynucleotides to κ -opioid receptor. Eur. J. Pharmacol. 253:1994;R7-R8.
11. Crooke S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32:1992;329-376.
12. Dutttaroy A., Yoburn B. C. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 82:1995;1226-1235.
13. Finney D. J. Probit analysis. 3rd ed. 1973;Cambridge University Press, London.
14. Hylden J. L. K., Wilcox G. L. Intrathecal morphine in mice: A new technique. Eur. J. Pharmacol. 67:1980;313-316.
15. Jenab S., Kest B., Inturrisi C. E. Assessment of delta opioid antinociception and receptor mRNA levels in mouse after chronic naltrexone treatment. Brain Res. 691:1995;69-75.
16. Lai J., Bilsky E. J., Porreca F. Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antonociceptive effects of delta subtype selective ligands. J. Recept. Signal Transduct. Res. 15:1995;643-650.
17. 2 -agonist antinociception. Neuroreport. 5:1994;1049-1052.
18. Lutfy K., Yoburn B. C. The role of opioid receptor density in morphine tolerance. J. Pharmacol. Exp. Ther. 256:1991;575-580.
19. Min B. H., Augustin L. B., Felsheim R., Fuchs J. A., Loh H. H. Genomic structure and analysis of promoter sequence of a mouse μ opioid receptor gene. Proc. Natl. Acad. Sci. USA. 91:1994;9081-9085.
20. 2 dopamine receptors. Mol. Pharmacol. 48:1995;730-737.
21. Rossi G., Pan Y.-X., Cheng J., Pasternak G. W. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci. 54:1994;PL375-PL379.
22. Rossi G. C., Pan Y.-X., Brown G. P., Pasternak G. W. Antisense mapping the MOR-1 opioid receptor: Evidence for alternative splicing and a novel morphine- 6β -glucuronide receptor. FEBS Lett. 369:1995;192-196.
23. Standifer K. M., Chien C.-C., Wahlestedt C., Brown G. P., Pasternak G. W. Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron. 12:1994;805-810.
24. Tempel A., Gardner E. L., Zukin R. S. Neurochemical and functional correlates of naltrexone-induced opiate receptor upregulation. J. Pharmacol. Exp. Ther. 232:1985;439-444.
25. Tseng L. F., Collins K. A. Antisense oligodeoxynucleotide to a δ -opioid receptor given intrathecally blocks ICV administered β -endorphin-induced antinociception in the mice. Life Sci. 55:1994;PL127-PL131.
26. Tseng L. F., Collins K. A., Kampine J. P. Antisense oligodeoxynucleotide to a δ -opioid receptor selectively blocks the spinal antinociception induced by δ -, but not μ - or κ -opioid receptor agonists in the mouse. Eur. J. Pharmacol. 258:1994;R1-R3.
27. Unterwald E. M., Rubenfeld J. M., Imai Y., Wang J. B., Uhl G. R., Kreek M. J. Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol. Brain Res. 33:1995;351-355.
28. Wahlestedt C., Golanov E., Yamamoto S., Yee F., Ericson H., Yoo H., Inturrisi C. E., Reis D. J. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect neurons from the excitotoxicity and reduce focal ischemic infarctions. Nature. 363:1993;260-263.
29. Wahlestedt C., Pich E. M., Koob G. F., Yee F., Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 259:1993;528-531.
30. 2 messenger RNA. Neurosci. 55:1993;607-612.
31. Yoburn B. C., Nunes F. C., Adler B., Pasternak G. W., Inturrisi C. E. Pharmacodynamic supersensitivity and opioid receptor upregulation in the mouse. J. Pharmacol. Exp. Ther. 239:1986;132-135.
32. Yoburn B. C., Luke M. C., Pasternak G. W., Inturrisi C. E. Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE. Life Sci. 43:1988;1319-1324.
33. Yoburn B. C., Shah S., Chan K. W., Duttaroy A., Davis T. Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: Relationship to receptor selectivity. Pharmacol. Biochem. Behav. 51:1995;535-539.
34. Yoburn B. C., Sierra V., Lutfy K. Chronic opioid antagonist treatment: Assessment of receptor upregulation. Eur. J. Pharmacol. 170:1989;193-200.
35. Zukin R. S., Sugarman J. R., Fitz-Syage M. L., Gardner E. L., Zukin S. R., Gintzler A. R. Naltrexone-induced opiate receptor supersensitivity. Brain Res. 245:1982;285-292.